Health-related quality of life and patient-centred outcomes with olaparib maintenance after chemotherapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT Ov-21): a placebo-controlled, phase 3 randomised trial

BACKGROUND: In the phase 3 SOLO2 trial (ENGOT Ov-21), maintenance therapy with olaparib tablets significantly prolonged progression-free survival (primary endpoint) compared with placebo in patients with a germline BRCA1 or BRCA2 (BRCA1/2) mutation and platinum-sensitive, relapsed ovarian cancer who...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Lancet Oncol
Main Authors: Friedlander, Michael, Gebski, Val, Gibbs, Emma, Davies, Lucy, Bloomfield, Ralph, Hilpert, Felix, Wenzel, Lari B, Eek, Daniel, Rodrigues, Manuel, Clamp, Andrew, Penson, Richard T, Provencher, Diane, Korach, Jacob, Huzarski, Tomasz, Vidal, Laura, Salutari, Vanda, Scott, Clare, Nicoletto, Maria Ornella, Tamura, Kenji, Espinoza, David, Joly, Florence, Pujade-Lauraine, Eric
Formato: Artigo
Idioma:Inglês
Publicado em: 2018
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7869962/
https://ncbi.nlm.nih.gov/pubmed/30026002
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1470-2045(18)30343-7
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados